Creating great software is a balance between multiple perspectives where favouring one perspective may be detrimental to another perspective. To add further complexity, these perspectives will vary depending on the project, the organisation, the team, or even the day. That said, there are a number of attributes to writing great software that are common to …
The recent discovery of N-nitrosamine (nitrosamine) impurities in several marketed pharmaceuticals has led to a requirement for further investigation into nitrosamine mutagenic and carcinogenic activity. Updated regulatory requirements mean that marketing authorisation holders for human medicines, containing chemically synthesised active substances, must review their medicines for the possible presence of nitrosamines and test all products at …
Lhasa Limited supports the global challenge of nitrosamine impurity assessment Read More »
In May, Lhasa hosted a webinar titled; The Application of Adverse Outcome Pathways (AOPs) for Risk Assessment. In case you missed this event, Senior Scientist, Alun Myden has provided an overview of the presentation and the work which Lhasa is doing in this area. An Introduction to AOPs AOPs are a formalised approach to documenting mechanisms …
The concept of pre-competitive collaborations and data sharing is currently in sharp focus with the current global collaborative efforts to combat Coronavirus, where the sharing of scientific knowledge is both urgent and critical for us to have a better chance of tackling the global pandemic. From the inception of Lhasa Limited in 1983, we’ve sought …
The Importance of Pre-competitive Collaborations Read More »
Coronaviruses and SARS-CoV-2 Coronaviruses are a large family of viruses which can affect humans or other species and can range anywhere from a mild illness such as the common cold to more severe illnesses such as Severe Acute Respiratory Syndrome (SARS). Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the novel severe acute …
Lhasa Limited supports an international initiative in the fight against COVID-19 Read More »
In his blog “Human review of in silico predictions of toxicity”, Principal Scientist, Alex Cayley, outlined the reasons why expert review is essential when using in silico tools to assess toxicity, particularly in the ICH M7 use case where expert review of two complementary in silico systems is required [1]. In this post we discuss how consideration of the user’s journey led …
Artificial Intelligence (AI) has become a powerful force within the pharmaceutical industry, catalysed by the challenging lengthy and costly drug development process. To maximize the impact of AI, it is critical to have access to enough good quality data to allow machine learning algorithms to extract relevant knowledge and produce valuable models. Despite the availability …
Effiris: A secondary pharmacology model suite powered by privacy-preserving data sharing Read More »
Human Review of In Silico Predictions of Toxicity: Some Key Questions for Consideration When Making An Assessment The speed by which models for toxicity prediction can be built and the accuracy with which they make predictions, have both improved greatly in recent years as a result of advances in technology, mechanistic understanding and access to …
Human review of in silico predictions of toxicity Read More »
Building QSAR models is easy. Building useful QSAR models is harder. Building QSAR models you can trust – well that can be really challenging – and this is where a lot of Lhasa’s effort is dedicated – creating models that can be used with confidence to make big decisions – such as those made during a …
One of the most important ingredients for an effective team is trust, and a critical phase of team building is starting to develop that sense of trust – to be strong has to be earnt and regularly reinforced; it is rarely simply given! The same is true when using in silico models and by mirroring …
Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK
Tel: +44 (0)113 394 6020
© 2023 Lhasa Limited, All rights reserved | Company Registration Number: 01765239 |
VAT Number: 396 8737 77 | Registered Charity Number: 290866